Klozapin çekilmesine bağlı ortaya çıkan katatoni: Bir olgu sunumu Katatoni şizofreninin bir alt tipi olmakla beraber katatonik tablolar bir çok farklı tıbbi durumda da karşımıza çıkabilmektedir. Klozapin çekilmesine bağlı ortaya çıkan katatoni tablosuyla ilgili az sayıda vaka bildirimi mevcuttur. Bu çalışmada klozapin kullanımını bıraktıktan beş gün sonra katatoni tablosuyla hastaneye başvuran 46 yaşında bir erkek hasta sunulmuştur. Hastanın 30 yıllık bilinen şizofreni tanısı olup rezidüel şizofreni tanısıyla 10 yıldır düzenli şekilde klozapin kullanmaktaydı. Onbir seans EKT uygulamasından fayda görmeyen hastaya klozapin başlanmasından sonra hızlı bir iyileşme gözlendi. Şizofreni hastalarında başka sebeplere bağlı olarak ortaya çıkan katatonik tablolar tanı karmaşasına ve dolayısıyla tedavide aksamalara yol açabileceğinden bu tip klinik durumların tanınması önemlidir.
ObjectiveIn this open-labeled, 12 weeks follow-up study, we aimed to compare the efficacy and tolerability of agomelatine with sertralineMethodsThe outpatients of adult psychiatry clinic who have a new onset of depression and diagnosed as ‘major depressive episode’ by clinician according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition and prescribed agomelatine (25 mg/day) or sertraline (50 mg/day) were included in the study.ResultsThe decline of mean Montgomery-Asberg Depression Rating Scale (MADRS) scores of agomelatine group was significantly higher than the sertraline group at the end of 2nd week; however, the difference was not significant at the end of 3 months. Mean Clinical Global Impression-Improvement scale (CGI-I) scores of agomelatine group was lower than sertraline group at first week. Mean CGI-Severity scale and CGI-I scores were favour to sertraline group at the end of the study. Remission rates were 46.7% for sertraline group and 33.3% for agomelatine group while response rates were 76.7% for both groups. Any patient from agomelatine group dropped-out due to adverse effects. The amount of side effects was also less with agomelatine.ConclusionAgomelatine has a rapid onset efficacy on depressive symptoms and this can be beneficial for some critical cases. Considering MADRS scores, agomelatine seems to have similar efficacy with sertraline but we also point the need for long term studies since CGI scores were favour to sertraline group at the end of the study. Agomelatine has a favourable tolerability profile both in terms of discontinuation and the amount of side effects compared to sertraline.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.